Insulet (PODD) Tops Q4 EPS by 10c

Insulet (NASDAQ: PODD) reported Q4 EPS of $0.42, $0.10 better than the analyst estimate of $0.32. Revenue for the quarter came in at $307.7 million versus the consensus estimate of $301.06 million.

GUIDANCE:

For the year ending December 31, 2022, the Company expects revenue growth in the range of 12% to 16%.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c